Got 90 seconds? Then listen to Actinogen Medical CEO and managing director Dr. Bill Ketelbey tell us about his AusBiotech Invest presentation and upcoming news-flow.

Actinogen Medical (ASX:ACW) is a biotechnology company focused on the development of innovative approaches for treating cognitive impairment associated with chronic neurological and metabolic diseases.

The company’s lead compound Xanamem, is a therapy under development for a number of conditions associated with cognitive impairment, including Alzheimer’s disease, a condition with multibillion-dollar market potential and material human impact.

In October Actinogen announced impressive efficacy results from XanaHES, its Phase I clinical trial assessing the safety and efficacy of 20mg Xanamem daily. The trial demonstrated a statistically significant cognitive improvement in the human trial subjects, a breakthrough result.

We caught up with Dr. Bill Ketelbey at the 2019 AusBiotech event and gave him 90 Seconds to tell us more about the company.

Have a good idea for our next 90 Seconds With segment? Email us at tv@stockhead.com.au.